Stony Brook U Licenses Novel Platform for Cancer Diagnosis and Treatment to Perspective Therapeutics

Stony Brook University and radiopharmaceutical company Perspective Therapeutics have entered into an exclusive license agreement to develop and commercialize a novel platform for the diagnosis and treatment of cancer.

Developed by researchers at Stony Brook, the Cuburbit[7]uril-admantane (CB7-Adma) pre-targeting platform has demonstrated promising in vivo stability, modularity, and low immunogenicity.

“This innovative radioligand treatment strategy circumvents the potential toxic side effects typically associated with directly radiolabeled monoclonal antibodies by employing a two-step targeting strategy utilizing the specificity of monoclonal antibodies with the safety and efficacy of radioligands,” says Jacob Houghton, assistant professor at Stony Brook.

Perspective’s exclusive license with the university covers the global intellectual property rights for the CB7-Adma pre-targeting platform.

Thijs Spoor, CEO of Perspective, comments, “By embracing a strategy that leverages the precision of monoclonal antibodies and the versatility of small molecules, Perspective has the opportunity to expand the therapeutic options available to patients receiving radiation therapy.”